Drawing shows that testosterone production is regulated by luteinizing hormone (LH) and luteinizing hormone-releasing hormone (LHRH). The hypothalamus releases LHRH, which stimulates the release of LH from the pituitary gland. LH acts on specific cells in the testes to produce the majority of testosterone in the body.

LHRH agonists. Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles. Treatment with these drugs is sometimes called medical castration because they lower androgen levels just as well as orchiectomy.

Luteinizing hormone-releasing hormone (LHRH) agonists and antagonists are commonly used androgen deprivation therapies prescribed for patients with advanced prostate cancer (PCa). Both types of agent target the receptor for LHRH but differ …

2024年11月15日 · Key data from major clinical studies are summarized, categorized by disease stage. LHRH-R agonists and antagonists, particularly goserelin, have demonstrated long-term survival benefits in patients with localized and locally advanced prostate cancer.

3 monthly and 6 monthly triptorelin and 3 monthly leuprorelin are the preferred cost effective LHRH agonists for prostate cancer in new patients. Switch guidance will need to be agreed by local Trust urologists for existing patients and should be considered at the next clinic appointment.

2009年6月9日 · Crawford and Hou[1] review the data on luteinizing hormone-releasing hormone (LHRH) antagonists in prostate cancer. They describe the results of a phase III trial comparing monthly degarelix to monthly leuprolide in men with advanced prostate cancer.

To define and describe the accepted indications for LHRH agonists or antagonist [Lupron Depot (leuprolide), Trelstar (triptorelin), Zoladex (goserelin), Firmagon (degarelix), Vantas (histrelin), Orgovyx (relugolix)] usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Key data from major clinical studies are summarized, categorized by disease stage. LHRH-R agonists and antagonists, particularly goserelin, have demonstrated long-term survival benefits in patients with localized and locally advanced prostate cancer.

• One type of hormone therapy, known as LHRH or GnRH agonists, are medications commonly used to reduces the amount of testosterone in a man’s body. • A second family of hormone therapy drugs, the anti-androgens, blocks the use of testosterone by the cancer cells.

The LHRH agonist mimics normal LHRH and fills the receptors of the pituitary gland that receive normal LHRH. For a period of 7 to 10 days, the pituitary gland perceives the LHRH agonist as normal LHRH and causes the testicles to produce large amounts of testosterone.